← All indications
Histiocytosis
General term for the abnormal appearance of histiocytes in the blood. Based on the pathological features of the cells involved rather than on clinical findings, the histiocytic diseases are subdivided into three groups: HISTIOCYTOSIS, LANGERHANS CELL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; and HISTIOCYTIC DISORDERS, MALIGNANT.
Subtype terms (3)
More specific conditions that are subtypes of Histiocytosis in the MeSH hierarchy.
- Histiocytic Disorders, Malignant
1 drug approved
- Histiocytosis, Langerhans-Cell
61 drugs (49 approved, 12 experimental)
- Histiocytosis, Non-Langerhans-Cell
Drugs by status
Phase 3 trials (2)
Phase 2 trials (15)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (23)
- Celgene
- Genentech
- Plexxikon
- Sanofi
- Accenture
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Cancer Institute (NCI)
- Hellenic Army
- Cornell University
- Harvard University
- Hellenic Society for the Study of Bone Metabolism
- New York Medical College
- University of Utah
- Tsinghua University
- Mesoblast, Inc.
- University of Texas at Houston
- Pennsylvania State University
- Methodist Cancer Center, Houston, Texas
- Cookies for Kids' Cancer
- St. Baldrick's Foundation
- Assisi Foundation
- Chinese Academy of Medical Sciences
- St. Jude Children's Hospital
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (2)